Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIVN 401

Drug Profile

BIVN 401

Alternative Names: BIVN-401; Methylene blue - Oklahoma Medical Research; Methylthioninium chloride - Oklahoma Medical Research; Suvus; Virostat

Latest Information Update: 15 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oklahoma Medical Research Foundation
  • Developer Bioenvision
  • Class Antivirals; Phenothiazines; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C
  • Discontinued Influenza virus infections; West Nile virus infections

Most Recent Events

  • 05 Dec 2008 No development reported - Preregistration for Hepatitis C in Egypt (PO)
  • 23 Oct 2007 Bioenvision has been acquired by Genzyme Corporation
  • 12 Sep 2007 Discontinued - Phase-II for Hepatitis C treatment in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top